Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

Shaibani, A. , Maallah, M. and Maallah, A. (2025) Antiviral Activity of Natural Compounds Immuno Formula Shiban2/5 against ...

CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 ...

A slow immune response to SARS-CoV-2 infection, delayed viral clearance, and viral rebound can all increase a person’s risk ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. According to official data, there have been ...

The current number of long COVID-19 cases may already be costing the U.S. $2.01–6.56 billion dollars per year, according to a ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

People who later experienced persistent shortness of breath or fatigue after a SARS-CoV-2 infection were already taking ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...